Ubs Group Ag Cue Biopharma, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 58,314 shares of CUE stock, worth $78,140. This represents 0.0% of its overall portfolio holdings.

Number of Shares

58,314

Previous 74,175 21.38%

Holding current value

$78,140

Previous $56,000 7.14%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$0.71 - $1.88 $11,261 - $29,818	-15,861 Reduced 21.38%	58,314 $60,000
Q3 2024 Nov 14, 2024	BUY	$0.45 - $1.08 $6,821 - $16,371	15,159 Added 25.69%	74,175 $56,000
Q2 2024 Aug 13, 2024	SELL	$1.24 - $2.18 $42,099 - $74,013	-33,951 Reduced 36.52%	59,016 $73,000
Q1 2024 May 13, 2024	SELL	$1.77 - $3.09 $11,140 - $19,448	-6,294 Reduced 6.34%	92,967 $175,000
Q4 2023 Feb 09, 2024	BUY	$1.72 - $3.1 $34,604 - $62,368	20,119 Added 25.42%	99,261 $262,000
Q3 2023 Nov 09, 2023	SELL	$2.23 - $4.69 $2,609 - $5,487	-1,170 Reduced 1.46%	79,142 $182,000
Q2 2023 Aug 11, 2023	BUY	$3.11 - $4.91 $69,300 - $109,409	22,283 Added 38.4%	80,312 $293,000
Q1 2023 May 12, 2023	BUY	$2.41 - $3.74 $81,660 - $126,726	33,884 Added 140.34%	58,029 $207,000
Q3 2022 Nov 10, 2022	SELL	$2.23 - $3.37 $9,535 - $14,410	-4,276 Reduced 15.05%	24,145 $54,000
Q2 2022 Aug 10, 2022	BUY	$2.49 - $5.92 $6,812 - $16,197	2,736 Added 10.65%	28,421 $71,000
Q1 2022 May 16, 2022	SELL	$4.41 - $12.28 $368,737 - $1.03 Million	-83,614 Reduced 76.5%	25,685 $126,000
Q4 2021 Feb 14, 2022	BUY	$10.86 - $17.85 $550,699 - $905,155	50,709 Added 86.55%	109,299 $1.24 Million
Q3 2021 Nov 15, 2021	BUY	$10.06 - $15.3 $317,624 - $483,066	31,573 Added 116.86%	58,590 $854,000
Q2 2021 Aug 13, 2021	SELL	$10.9 - $14.53 $276,914 - $369,134	-25,405 Reduced 48.46%	27,017 $315,000
Q1 2021 May 12, 2021	BUY	$11.2 - $16.09 $334,734 - $480,881	29,887 Added 132.62%	52,422 $640,000
Q4 2020 Feb 11, 2021	BUY	$11.12 - $16.4 $10,452 - $15,415	940 Added 4.35%	22,535 $282,000
Q2 2020 Jul 31, 2020	SELL	$12.7 - $30.73 $118,872 - $287,632	-9,360 Reduced 30.24%	21,595 $529,000
Q1 2020 May 01, 2020	SELL	$9.85 - $22.27 $274,499 - $620,620	-27,868 Reduced 47.38%	30,955 $439,000
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $72,788 - $180,115	10,310 Added 21.25%	58,823 $933,000
Q3 2019 Nov 14, 2019	BUY	$6.78 - $9.28 $82,675 - $113,160	12,194 Added 33.57%	48,513 $409,000
Q2 2019 Aug 14, 2019	BUY	$7.18 - $9.65 $42,699 - $57,388	5,947 Added 19.58%	36,319 $326,000
Q1 2019 May 14, 2019	SELL	$4.7 - $9.29 $32,820 - $64,872	-6,983 Reduced 18.69%	30,372 $235,000
Q4 2018 Feb 14, 2019	BUY	$4.35 - $8.73 $48,907 - $98,151	11,243 Added 43.06%	37,355 $175,000
Q3 2018 Nov 14, 2018	BUY	$7.91 - $11.89 $23,381 - $35,146	2,956 Added 12.77%	26,112 $236,000
Q2 2018 Aug 14, 2018	BUY	$10.93 - $14.48 $212,708 - $281,795	19,461 Added 526.68%	23,156 $275,000
Q1 2018 May 15, 2018	BUY	$11.63 - $17.25 $42,972 - $63,738	3,695 New	3,695 $52,000

Others Institutions Holding CUE

# of Institutions

Shares Held

11.9M

Call Options Held

22K

Put Options Held

1.2K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $47.4M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account